Skip to main content

Table 3 Health states utility value scores at baseline and follow-up

From: Psychological therapy for mood instability within bipolar spectrum disorder: a randomised, controlled feasibility trial of a dialectical behaviour therapy-informed approach (the ThrIVe-B programme)

Outcomea

Baseline

3-month follow-up

6-month follow-up

9-month follow-up

15-month follow-up

ThrIVe-B

TAU

ThrIVe-B

TAU

ThrIVe-B

TAU

ThrIVe-B

TAU

ThrIVe-B–TAUb (95% CI)

ThrIVe-B

TAU

EQ-5D-3L

0.52 (0.30)

[− 0.18, 1]

n = 20

 

0.65 (0.25)

[0.08, 1]

n = 13

0.59 (0.36)

[− 0.18, 0.85]

n = 14

0.51 (0.31)

[− 0.02, 1]

n = 14

0.65 (0.33)

[− 0.18, 1]

n = 16

0.63 (0.29)

[0.08, 1]

n = 14

0.63 (0.35)

[− 0.08, 1]

n = 17

0.15

(− 0.12, 0.41)

n = 28

0.64 (0.31)

[0.08, 1]

n = 10

0.57 (0.35)

[− 0.02, 1]

n = 16

SF-36

0.58 (0.15)

[0.26, 0.85]

n = 20

0.64 (0.11)

[0.46, 0.86]

n = 20

0.63 (0.12)

[0.39, 0.81]

n = 13

0.63 (0.12)

[0.40, 0.81]

n = 17

0.63 (0.10)

[0.50, 0.86]

n = 14

0.64 (0.13)

[0.40, 0.86]

n = 17

0.64 (0.14)

[0.37, 0.88]

n = 13

0.60 (0.13)

[0.32, 0.88]

n = 16

0.11

(0.01, 0.20)

n = 29

0.65 (0.12)

[0.43, 0.85]

n = 10

0.62 (0.11)

[0.45 0.88]

n = 15

  1. aOutcomes are reported as mean (SD) [range] unless otherwise stated
  2. bAdjusted for site, base use of bipolar disorder medication and baseline score